Sean A. Power - Jul 20, 2022 Form 4 Insider Report for TG THERAPEUTICS, INC. (TGTX)

Role: Chief Financial Officer
Signature: /s/ Sean A. Power
Stock symbol: TGTX
Transactions as of: Jul 20, 2022
Transactions value $: $0
Form type: 4
Date filed: 7/22/2022, 04:33 PM
Previous filing: Jan 7, 2022
Next filing: Mar 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TGTX	Common Stock	Award	$0	+75K	+13.19%	$0.00	643K	Jul 20, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TGTX	Employee Stock Option (right to buy)	Award	$0	+200K		$0.00	200K	Jul 20, 2022	Common Stock, par value $0.001	200K	$7.00	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects a grant of restricted shares, of which 1/3 will vest on 1/1/2023, 1/3 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis, and 1/3 will vest upon approval by the European Medicines Agency of ublituximab.
F2	Includes shares of restricted Common Stock, which vest over various time periods.
F3	Reflects a grant of options relating to 2021 service and performance, of which 1/2 will vest on 1/1/2024 and 1/2 will vest upon U.S. Food and Drug Administration approval of ublituximab as a treatment for patients with relapsing forms of multiple sclerosis.